Potassium-competitive acid blockers (P-CABs)
Acid blockers that bind the proton pump at its potassium site, reversibly and without needing acid activation, unlike PPIs.
What they are
A newer class of gastric acid suppressants for erosive oesophagitis, reflux and Helicobacter pylori eradication. They block the same H+/K+-ATPase as proton pump inhibitors but in a different way, giving fast and long acid control.
Mechanism of action
P-CABs are weak bases that concentrate in the acid space of the parietal cell and bind competitively and reversibly to the potassium-binding site of the H+/K+-ATPase. Unlike PPIs they are not prodrugs, do not need acid to be activated and do not bind covalently, so the effect starts quickly. They depend less on CYP2C19 than PPIs.
Target: Gastric H+/K+-ATPase (proton pump), at its potassium-binding site
Drugs in this class
Others in the class
- Tegoprazan
- Revaprazan
- Fexuprazan
Test yourself
Think of the answer, then tap the question to see it.
How does a P-CAB bind the proton pump differently from a PPI?
Reversibly and competitively at the potassium site, without acid activation; PPIs are acid-activated prodrugs that bind covalently.
Which indications does it share with PPIs?
Erosive oesophagitis, reflux, or H. pylori eradication with antibiotics.
Which CYP enzyme matters less for P-CABs than for PPIs?
CYP2C19.
Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given.
Sources: Vonoprazan: MedlinePlus Drug Information (MedlinePlus (U.S. National Library of Medicine), 2026); ATCDDD - ATC/DDD Index (WHO Collaborating Centre for Drug Statistics Methodology, 2026); RCSB PDB - 5YLU: Crystal structure of the gastric proton pump complexed with vonoprazan (RCSB Protein Data Bank, 2026).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.